Pharmaceutical - Financial, Gastro-intestinals


Popular Filters

Furiex shares double after top-line results of IBS drug eluxadoline in two Phase III studies

Furiex shares double after top-line results of IBS drug eluxadoline in two Phase III studies


Furiex Pharmaceuticals has announced top-line results from two pivotal Phase III clinical trials evaluating…

FinancialFuriex PharmaceuticalsGastro-intestinalsPharmaceuticalResearchUSA

Nektar hedges bets on deal with AstraZeneca


Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC


USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC


UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…


Merck & Co to continue posting sales and profits under AstraZeneca partnership


US drug giant Merck & Co (NYSE: MRK) and Anglo-Swedish major AstraZeneca have amended the option agreement…

AstraZenecaFinancialGastro-intestinalsLicensingMerck & CoNexiumPharmaceuticalPrilosec

Astellas and Drais partner to develop IBS compound through Seldar


Japanese drug major Astellas Pharma (Tokyo: 4503) has entered into a second partnership in as many month…

ASP3291Astellas PharmaDrais PharmaceutialsFinancialGastro-intestinalsPharmaceuticalResearchSeldar Pharma

Back to top